Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Krijn P. van Lienden

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7102-2213; OpenAlex author ID A5059092900. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 17

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  3. Quantitative analysis of contribution of mild and moderate hyperthermia to thermal ablation and sensitization of irreversible electroporation of pancreatic can… Co-author DOI 10.1016/j.jtherbio.2023.103619↗
  4. Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): pros… Co-author DOI 10.1007/s00423-022-02653-y↗
  5. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of t… Co-author DOI 10.1002/jso.26567↗
  6. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Co-author DOI 10.1016/j.ejso.2020.11.137↗
  7. Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-… Co-author DOI 10.1097/sla.0000000000005120↗
  8. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled… Co-author DOI 10.1186/s13063-021-05248-y↗
  9. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32586↗
  10. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison. Co-author DOI 10.1016/j.jvir.2020.02.024↗
  11. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Stu… Co-author DOI 10.1148/radiol.2019191109↗
  12. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a pro… Last author DOI 10.1016/j.hpb.2019.02.017↗
  13. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Co-author DOI 10.3390/cancers11070976↗
  14. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. Co-author DOI 10.1016/j.hpb.2018.01.001↗
  15. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Co-author DOI 10.1245/s10434-017-5900-9↗
  16. Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer. Co-author DOI 10.1002/bjs.10148↗
  17. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1002/bjs.9716↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 16 shared papers, 2015–2024 · strength 1.46
  2. Johanna W. Wilmink · 9 shared papers, 2017–2022 · strength 0.75
  3. Eran van Veldhuisen · 7 shared papers, 2018–2023 · strength 0.71
  4. Izaak Quintus Molenaar · 8 shared papers, 2015–2024 · strength 0.70
  5. Hjalmar C. van Santvoort · 8 shared papers, 2015–2024 · strength 0.70
  6. Ignace H. J. T. de Hingh · 7 shared papers, 2019–2024 · strength 0.69
  7. Jantien A. Vogel · 6 shared papers, 2015–2023 · strength 0.53
  8. Marieke S. Walma · 6 shared papers, 2019–2021 · strength 0.50
  9. Gijs A. Patijn · 5 shared papers, 2021–2024 · strength 0.50
  10. Vincent Erwin de Meijer · 5 shared papers, 2021–2024 · strength 0.50
  11. Sebastiaan Festen · 5 shared papers, 2021–2024 · strength 0.50
  12. Martijn W.J. Stommel · 5 shared papers, 2021–2024 · strength 0.50
  13. Martijn Ruben Meijerink · 5 shared papers, 2019–2021 · strength 0.43
  14. Lilly J. H. Brada · 5 shared papers, 2019–2021 · strength 0.42
  15. Hanneke W.M. van Laarhoven · 5 shared papers, 2017–2022 · strength 0.42
  16. Geert Kazemier M · 3 shared papers, 2020–2024 · strength 0.34
  17. Lois A. Daamen · 3 shared papers, 2021–2024 · strength 0.34
  18. Nadia Haj Mohammad · 4 shared papers, 2019–2021 · strength 0.33
  19. Bas Groot Koerkamp · 3 shared papers, 2019–2024 · strength 0.32
  20. Steffi J. E. Rombouts · 4 shared papers, 2015–2021 · strength 0.27
  21. Maarten Simon van Leeuwen · 3 shared papers, 2019–2021 · strength 0.24
  22. Thijs J. Schouten · 2 shared papers, 2021–2024 · strength 0.23
  23. Geertjan van Tienhoven · 2 shared papers, 2019–2024 · strength 0.22
  24. Hendrik A. Marsman · 2 shared papers, 2018–2022 · strength 0.20
  25. L. Bengt van Rijssen · 2 shared papers, 2019–2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.